NAD+

NAD+ Precursors: Nicotinamide Riboside and NMN

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Nicotinamide riboside is 255.25 Da and nicotinamide mononucleotide is 334.22 Da. Both are precursors cells convert into NAD+ through the salvage pathway, and both are small enough to be taken up in ways NAD+ itself is not, which is why almost all human trial data uses them.

Key facts

NR
255.25 Da, C11H15N2O5+, CID 439924
NMN
334.22 Da, C11H15N2O8P, CID 14180
NAD+
663.4 Da, over twice NR
Route
Salvage pathway
NR to NMN
Phosphorylation by NRK enzymes
NMN to NAD+
Adenylylation by NMNAT

The salvage pathway

Cells do not usually build NAD+ from scratch. They recycle it from nicotinamide-containing fragments, the products of NAD+ consumption by sirtuins, PARPs and CD38. Supplying NR or NMN feeds that existing recycling route rather than establishing a new one, which is why both work as precursors at all.

How each enters

NR is phosphorylated by nicotinamide riboside kinases to make NMN. NMN is then adenylylated by NMNAT enzymes to make NAD+. So NR is one step further back than NMN, and NMN is the immediate precursor. NR crosses into the cell as the smaller uncharged-at-that-position molecule; NMN's route has been the subject of more debate, since it carries a phosphate.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Why size and charge decide this

NR at 255.25 Da is under 40% of NAD+'s mass and lacks the pyrophosphate bridge entirely. NMN at 334.22 Da carries one phosphate rather than two. Both are substantially less encumbered than the finished coenzyme, and the pattern is consistent: the further back down the pathway, the easier the molecule is to deliver.

What the trials used

NADPARK, published in Cell Metabolism in 2022, was a randomised phase I trial of nicotinamide riboside in Parkinson's disease. Orr and colleagues ran a randomised placebo-controlled trial of NR in older adults, published in GeroScience in 2024. Yoshino and colleagues published NMN work in Science in 2021. The precursor choice is uniform across the serious literature.

Which is better

Not settled, and the question is more contested than either side's marketing suggests. NR has more published randomised trial data; NMN has the higher-profile single result in Yoshino's Science paper. Both raise measured NAD+-related markers in at least some tissues. Neither has demonstrated the downstream clinical outcomes the field is interested in.

Quick reference

MWPhosphatesSteps to NAD+
Nicotinamide riboside255.25 DaNoneTwo
Nicotinamide mononucleotide334.22 DaOneOne
NAD+663.4 DaTwo-

Frequently asked questions

What is the difference between NR and NMN?

NR is one step further back in the pathway. Cells phosphorylate NR to NMN, then convert NMN to NAD+.

Which has more trial data?

NR, including NADPARK in Cell Metabolism 2022 and a placebo-controlled study in older adults in GeroScience 2024. NMN's highest-profile result is Yoshino 2021 in Science.

Why not just supply NAD+?

It is over twice NR's mass, carries two negative charges, and does not cross membranes. Precursors do.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.